Clinician reference tool — not medical advice. This is a clinical decision-aid intended for healthcare professionals: it gives deterministic suggestions to think with, not a diagnosis or a prescription. If you’re a patient, you’re welcome to look around — but please review anything here with your own doctor; it isn’t a substitute for personalized medical care.

Evidence: Canadian Consensus Guidelines for AD — topical therapies … 2025 · sources last checked 2026-08-20

Reference tool — not medical advice. Thresholds, targets, and first-line agents differ by guideline body and change over time — switch the lens to compare. Clinician judgement, dosing/monitoring, contraindications, and live coverage always required. Runs entirely in your browser — no data is collected.

Eczema / atopic dermatitis selector

Choose the guideline lens (Canadian / AAD / EuroGuiDerm), enter severity, site and context — get the stepped therapy: emollients + topical steroid (potency by site), calcineurin inhibitors for face/flexures, and for moderate-severe disease dupilumab (first-line biologic) with JAK inhibitors positioned after biologics in Canada.

Guideline lens

Severitychoose one

Predominant sitechoose one

Age groupchoose one

Context

Severity tier

Mild

Systemic-eligible?

No — optimize topical therapy first

Notes

  • • Canadian coverage: dupilumab via provincial EAP-type programs (after topical/conventional failure); tralokinumab/lebrikizumab and oral JAK inhibitors are reimbursement-constrained (individualized funding); several new topicals (tapinarof/roflumilast/ruxolitinib cream) are not yet reliably Health Canada-approved — verify before prescribing.

Suggested drug classesPer Canadian consensus 2025.

Select severity and predominant site to begin.

Switch the lens to see the JAK-vs-biologic sequencing difference: Canadian (biologics-first, JAK after) vs AAD (parallel options).

Guidelines

References

  1. [1]Canadian Consensus Guidelines for AD — topical therapies (Dermatol Ther 2025) + systemic-eligible AD consensus (JAAD Int 2025; biologics-first, JAK after). link
  2. [2]AAD Guidelines of care for atopic dermatitis in adults — topical (2023) + 2025 focused update (tapinarof, roflumilast). JAAD. link
  3. [3]EuroGuiDerm European guideline on atopic eczema — systemic therapy (2022) + 2025 living update (lebrikizumab, nemolizumab). link